Soquelitinib

Phase 3Small molecule

CCorvus Pharmaceuticals, Inc.

Soquelitinib is one of 86 small molecule programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis Suppurativa (HS)Not yet recruiting

Autoimmune Lymphoproliferative SyndromeRecruiting

ARTRecruiting

LymphomaRecruiting

Hidradenitis Suppurativa (HS)Phase 1

Not yet recruiting

Autoimmune Lymphoproliferative SyndromePhase 2

Recruiting

ARTPhase 2

Recruiting

LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Autoimmune Lymphoproliferative Syndrome

NCT06730126

Q3 2027

Phase 2Recruiting

ART

NCT07441395

Q4 2027

Phase 1Not yet recruiting

Hidradenitis Suppurativa (HS)

NCT07828860

Q3 2028

Phase 3Recruiting

Lymphoma

NCT06561048

Clinical

Trials by Indication[1]

Efficacy1 trial

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Completed·CCorvus Pharmaceuticals, Inc.·Phase 1·NCT06345404·82 enrolled

Lymphoma1 trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Recruiting·CCorvus Pharmaceuticals, Inc.·Phase 3·NCT06561048·150 enrolled

ART1 trial

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Recruiting·CCorvus Pharmaceuticals, Inc.·Phase 2·NCT07441395·200 enrolled

Hidradenitis Suppurativa (HS)1 trial

A Phase 1b, Open-label Study Evaluating the Safety and Efficacy of Oral Soquelitinib in Adults With Moderate-to-Severe Hidradenitis Suppurativa

Not yet recruiting·CCorvus Pharmaceuticals, Inc.·Phase 1·NCT07828860·25 enrolled

Autoimmune Lymphoproliferative Syndrome1 trial

A Phase 2a Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06730126·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Soquelitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Soquelitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Soquelitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corvus Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCorvus Pharmaceuticals, Inc.

Soquelitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Efficacy1 trial

Lymphoma1 trial

ART1 trial

Hidradenitis Suppurativa (HS)1 trial

Autoimmune Lymphoproliferative Syndrome1 trial

References

Drug Info

Quick Facts

Related News